Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? - PubMed (original) (raw)
. 2007 Feb 13;49(6):657-66.
doi: 10.1016/j.jacc.2006.10.050. Epub 2007 Jan 26.
Affiliations
- PMID: 17291930
- DOI: 10.1016/j.jacc.2006.10.050
Free article
Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Kevin P Bliden et al. J Am Coll Cardiol. 2007.
Free article
Abstract
Objectives: We sought to determine whether patients receiving chronic clopidogrel therapy undergoing nonemergent stenting who display high on-treatment preprocedural platelet aggregation measured by standard light transmittance aggregometry and thrombelastography (TEG) will be at increased risk for poststenting ischemic events.
Background: Patients exhibiting heightened platelet reactivity to adenosine diphosphate (ADP) might be at increased risk for recurrent ischemic events after coronary stenting.
Methods: A total of 100 consecutive patients receiving chronic antiplatelet therapy consisting of aspirin (325 mg qd) and clopidogrel (75 mg qd) were studied before undergoing nonemergent stenting. Patients were followed for 1 year after coronary stenting for the occurrence of death, myocardial infarction, stent thrombosis, stroke, or ischemia requiring a hospital stay.
Results: All patients were aspirin responsive. Patients with ischemic events (23 of 100, 23%) within 1 year had greater on-treatment prestent ADP-induced platelet aggregation than patients without ischemic events by aggregometry and TEG (p < 0.001 for both measurements). Of patients with an ischemic event, 70% and 87% displayed high on-treatment platelet reactivity at baseline by aggregometry and TEG, respectively. High on-treatment platelet reactivity as measured by aggregometry and TEG were the only variables significantly related to ischemic events (p < 0.001 for both assays). The administration of eptifibatide reduced periprocedural elevation in platelet reactivity, with no significant differences in bleeding events.
Conclusions: Patients receiving chronic clopidogrel therapy undergoing nonemergent percutaneous coronary intervention who exhibit high on-treatment ADP-induced platelet aggregation are at increased risk for postprocedural ischemic events. These findings might have implications for the alteration in clopidogrel maintenance dose and use of glycoprotein IIb/IIIa inhibitors in selected patients.
Similar articles
- Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, Lehmann A, Lambert M, Bonnet JL, Alessi MC. Cuisset T, et al. J Am Coll Cardiol. 2006 Oct 3;48(7):1339-45. doi: 10.1016/j.jacc.2006.06.049. Epub 2006 Sep 12. J Am Coll Cardiol. 2006. PMID: 17010792 Clinical Trial. - High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Mielot C, Bali L, Lambert M, Alessi MC, Bonnet JL. Cuisset T, et al. Thromb Haemost. 2007 Feb;97(2):282-7. Thromb Haemost. 2007. PMID: 17264958 - Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, Tantry US. Gurbel PA, et al. Platelets. 2008 Dec;19(8):595-604. doi: 10.1080/09537100802351065. Platelets. 2008. PMID: 19012177 - Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z, Kala P. Motovska Z, et al. Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Clin Ther. 2008. PMID: 19281914 Review.
Cited by
- Clinical Application of Thromboelastography in Acute Ischemic Stroke.
Chen F, Zhang L, Bai X, Wang X, Geng Z. Chen F, et al. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221131801. doi: 10.1177/10760296221131801. Clin Appl Thromb Hemost. 2022. PMID: 36285384 Free PMC article. Review. - Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis.
Zhang H, Lauver DA, Wang H, Sun D, Hollenberg PF, Chen YE, Osawa Y, Eitzman DT. Zhang H, et al. J Pharmacol Exp Ther. 2016 Oct;359(1):11-7. doi: 10.1124/jpet.116.236034. Epub 2016 Aug 10. J Pharmacol Exp Ther. 2016. PMID: 27511819 Free PMC article. - Clinical characteristics associated with high on-treatment platelet reactivity of patients undergoing PCI after a 300 mg loading dose of clopidogrel, measured by thrombelastography.
Hou XM, Han WZ, Qiu XB, Fang WY. Hou XM, et al. Heart Asia. 2013 May 9;5(1):66-9. doi: 10.1136/heartasia-2013-010296. eCollection 2013. Heart Asia. 2013. PMID: 27326080 Free PMC article. - Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.
Arai T, Kawamura A, Matsubara Y, Yokoyama K, Ikeda Y, Fukuda K, Murata M. Arai T, et al. Heart Vessels. 2012 Sep;27(5):480-5. doi: 10.1007/s00380-011-0180-y. Epub 2011 Aug 12. Heart Vessels. 2012. PMID: 21837496 - Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.
Regev E, Asher E, Fefer P, Beigel R, Mazin I, Matetzky S; Platelets and Thrombosis in Sheba (PLATIS) - Study Group. Regev E, et al. PLoS One. 2018 Apr 6;13(4):e0195504. doi: 10.1371/journal.pone.0195504. eCollection 2018. PLoS One. 2018. PMID: 29624604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical